Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023
Other Players Ahead In The Race Tipped To Launch Late 2023/Early 2024
At the European Society of Rheumatology conference currently taking place in Milan, Italy, Celltrion unveiled progress for its proposed biosimilar to Roche’s Actemra/RoActemra (tocilizumab).
